No abstract available.
Adenocarcinoma* ; alpha-Fetoproteins*

No abstract available.
alpha-Fetoproteins* ; Mass Screening*

No abstract available.
alpha-Fetoproteins* ; Prenatal Diagnosis*

Hepatoid carcinoma is histologically similar to hepatocelluar carcinoma and produce alfa-fetoprotein. Ovarian hepatoid carcinoma is extremely rare whether primary or metastatic. We experienced one case of primary ovarian hepatoid carcinoma. In this case report, we present histologic findings, therapeutic modalities of primary hepatoid carcinoma with review of literatures.
alpha-Fetoproteins ; Female ; Ovary

The authors used radioimmunoassay (RIA) method for determining AFP and CEA concentrations in the blood of healthy adults and cancer patients. The results are follow: 1. Serum AFP concentration in the blood of healthy adults is 2.67+/-1.21 IU/ml, n=81 (from 0 to 5 IU/ml) and CEA concentration is 3.95+/- 1.12ng/ml (from 0 to 6 ng/ml). 2. The serum AFP concentration is higher in patients with hepatic cirrhosis and chronic hepatitis and more higher in the group of patients with primary cancer of liver. In serum of patients with cancer of stomach, colorectal and bronchi, the CEA concentrations are significantly increased than healthy. So RIA method determining CEA, AFP concentrations in serum has an important value in diagnosing cancer of liver, gastrointestinal tract and bronchi.
neoplasms ; alpha-Fetoproteins

Lot-to-lot reproducibility is an important issue in immunoassays and reagent lot-to-lot comparability test comparing the results of new reagent lot with those of used lot using patients' samples or controls is usually performed to detect the difference between lots. However, there are no universally used acceptability criteria regarding reagent lot-to-lot comparability test. We performed reagent comparability test between different lots of alpha-fetoprotein (AFP) reagents and tried to determine its comparability by several criteria. Both the commercialized controls and in-house controls for AFP made from pooled patients' sera were measured 10 times using the old and new lots of reagents, whenever a reagent lot was changed. The differences in the mean control values, the percent difference (% difference), and the difference to between-run standard deviation ratio (D:SD ratio) between successive lots were calculated. We compared the results of reagent comparability test to arbitrarily determined acceptability criteria suggested by CLSI C54-A. Although comparability between reagent lots was determined according to how strictly we set the criteria, some lot-to-lot differences between certain pairs of lots exceeded the criteria. We hope that the results of this study might be helpful to perform reagent lot-to-lot comparability test and set the criteria for reagent comparability test between lots in other laboratories.
alpha-Fetoproteins ; Immunoassay ; Indicators and Reagents

No abstract available.
alpha-Fetoproteins* ; Humans ; Infant, Newborn*

Background: Radiofrequency ablation (RFA) is a minimally invasive treatment for hepatocellular carcinoma (HCC). It is coming into use worldwide. Objective: To analyze clinical characteristics, AFP (alpha - feto protein), imaging features of liver tumors after treated with RFA or with RFA combined with TOCE. Subjects and method: Between August 2002 and October 2006, we ablated 87 HCCs in 76 patients (RFA alone, 41. TOCE - RFA, 35). Results: The mean age of patients was 52.8 \xb1 12. The male/female ratio was 5.9/1. The complication rate was 1.9% (5/254 sessions, 5/76 patients). Significant differences were observed in clinical symptoms: Weigh gain, abdominal pain relief, AFP decreased after treatment. Median survival was 30 \xb1 5.8 months in RFA group and 31 \xb1 5.4 months in TOCE - RFA group. 1 - 2 - 3 years survival rates were 74%; 56.3%; 43.8% in RFA group and 91.3%; 63.4%; 34.6% in TOCE - RFA group. Ablated lesions were of low attenuation with absence of contrast material enhancement and reduced in size. Conclusions: Our study results show that RFA is an effective and safe therapeutic technique for HCC. Good therapeutic effects on clinical symptoms, treated lesion and survival were achieved.
Carcinoma ; Hepatocellular/ therapy ; Alpha-Fetoproteins

No abstract available.
alpha-Fetoproteins* ; Humans ; Infant* ; Infant, Newborn*

No abstract available.
alpha-Fetoproteins* ; Infant, Newborn ; Jaundice, Neonatal* ; Plasma*